{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T12:07:42Z","timestamp":1783944462063,"version":"3.55.0"},"reference-count":77,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012246","name":"Priority Academic Program Development of Jiangsu Higher Education Institutions","doi-asserted-by":"publisher","award":["SJCX23-0785"],"award-info":[{"award-number":["SJCX23-0785"]}],"id":[{"id":"10.13039\/501100012246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Adrenocortical carcinoma (ACC) is an uncommon and highly aggressive cancer originating in the adrenal cortex, characterized by a high likelihood of recurrence and unfavorable survival rates, particularly in the advanced disease stages. This review discusses the complex molecular pathogenesis of ACC, focusing on critical pathways implicated in the tumorigenesis and providing potential targets for therapy: the Wnt\/\u03b2-catenin signaling pathway, the IGF2\/IGF1R axis, and the apoptosis pathway regulated by p53. Current treatment strategies include surgical resection and mitotane, the sole adrenolytic agent approved by the FDA; however, its effects in advanced disease are suboptimal. Cytotoxic chemotherapy combined with mitotane may be applied, but survival benefits are limited so far. In the following review, we outline emerging targeted therapies, such as mTOR inhibitors and tyrosine kinase inhibitors (TKIs), which show favorable preclinical and clinical data, especially in treatment-resistant ACC. We also emphasize the possible role of immune checkpoint inhibitors (ICIs) in the management of ACC, although their effectiveness is still under study. Upcoming trends in treatment involve forms of personalized medicine, where molecular profiling is integrated to identify actionable biomarkers for administered therapies. This review will attempt to provide a comprehensive framework on how recent breakthroughs in the genomics of ACC, coupled with advances in targeted therapies and immunotherapy, can improve management.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1545012","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T08:10:11Z","timestamp":1741767011000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Therapeutic strategies for adrenocortical carcinoma: integrating genomic insights, molecular targeting, and immunotherapy"],"prefix":"10.3389","volume":"16","author":[{"given":"Jing","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxuan","family":"Huai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Run","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanbin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minglun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuehua","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiqiao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1177\/20406223211033103","article-title":"Adrenocortical carcinoma: current state of the art, ongoing controversies, and future directions in diagnosis and treatment","volume":"12","author":"Shariq","year":"2021","journal-title":"Ther Adv Chronic Disease"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr3503w","article-title":"The characteristics and trends in adrenocortical carcinoma: A united states population based study","volume":"10","author":"Sharma","year":"2018","journal-title":"J Clin Med Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.02.034","article-title":"Adrenocortical carcinoma: a population-based study on incidence and survival in the netherlands since 1993","volume":"49","author":"Kerkhofs","year":"2013","journal-title":"Eur J Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2856","article-title":"Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma","volume":"99","author":"Else","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2639","article-title":"Adrenocortical carcinoma: Clinical update","volume":"91","author":"Allolio","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-00918","article-title":"Predictors of survival in adrenocortical carcinoma: An analysis from the national cancer database","volume":"103","author":"Tella","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-019-0221-7","article-title":"Adrenocortical carcinoma - towards genomics guided clinical care","volume":"15","author":"Crona","year":"2019","journal-title":"Nat Rev Endocrinol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-023-00623-0","article-title":"Advances in translational research of the rare cancer type adrenocortical carcinoma","volume":"23","author":"Ghosh","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2018.04.068","article-title":"Longitudinal patterns of recurrence in patients with adrenocortical carcinoma","volume":"165","author":"Glenn","year":"2019","journal-title":"Surgery"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpedsurg.2013.02.017","article-title":"Predictors of survival in pediatric adrenocortical carcinoma: a surveillance, epidemiology, and end results (SEER) program study","volume":"48","author":"McAteer","year":"2013","journal-title":"J Pediatr Surg"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2020.101415","article-title":"New perspectives for mitotane treatment of adrenocortical carcinoma","volume":"34","author":"Puglisi","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa063360","article-title":"Adjuvant mitotane treatment for adrenocortical carcinoma","volume":"356","author":"Terzolo","year":"2007","journal-title":"New Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European society of endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the european network for the study of adrenal tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.04.002","article-title":"Comprehensive pan-genomic characterization of adrenocortical carcinoma","volume":"29","author":"Zheng","year":"2016","journal-title":"Cancer Cell"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-020-1358-5","article-title":"Wnt\/\u03b2-catenin activation cooperates with loss of p53 to cause adrenocortical carcinoma in mice","volume":"39","author":"Borges","year":"2020","journal-title":"Oncogene"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2020.111120","article-title":"\u03b2-catenin in adrenal zonation and disease","volume":"522","author":"Little","year":"2021","journal-title":"Mol Cell Endocrinology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.canlet.2020.10.022","article-title":"The cytoskeleton actin binding protein filamin a impairs both IGF2 mitogenic effects and the efficacy of IGF1R inhibitors in adrenocortical cancer cells","volume":"497","author":"Catalano","year":"2021","journal-title":"Cancer Lett"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-019-02033-5","article-title":"IGF2 role in adrenocortical carcinoma biology","volume":"66","author":"Pereira","year":"2019","journal-title":"Endocrine"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-022-03074-z","article-title":"FGF\/FGFR signaling in adrenocortical development and tumorigenesis: novel potential therapeutic targets in adrenocortical carcinoma","volume":"77","author":"Tamburello","year":"2022","journal-title":"Endocrine"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.795116","article-title":"Role of FGF receptors and their pathways in adrenocortical tumors and possible therapeutic implications","volume":"12","author":"Sbiera","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12967-022-03277-y","article-title":"CENPF\/CDK1 signaling pathway enhances the progression of adrenocortical carcinoma by regulating the G2\/M-phase cell cycle","volume":"20","author":"Huang","year":"2022","journal-title":"J Transl Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"417","DOI":"10.7150\/jca.80097","article-title":"Potential clinical treatment prospects behind the molecular mechanism of alternative lengthening of telomeres (ALT)","volume":"14","author":"Sun","year":"2023","journal-title":"J Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222011101","article-title":"Pan-cancer analysis of clinical relevance via telomere maintenance mechanism","volume":"22","author":"Sung","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecoenv.2022.113982","article-title":"Fluorene-9-bisphenol regulates steroidogenic hormone synthesis in H295R cells through the AC\/cAMP\/PKA signaling pathway","volume":"243","author":"Huang","year":"2022","journal-title":"Ecotoxicology Environ Safety"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2019.110636","article-title":"Link between steroidogenesis, the cell cycle, and PKA in adrenocortical tumor cells","volume":"500","author":"Rizk-Rabin","year":"2020","journal-title":"Mol Cell Endocrinology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103617","article-title":"Comprehensive genomic analysis of adrenocortical carcinoma reveals genetic profiles associated with patient survival","volume":"9","author":"Sun-Zhang","year":"2024","journal-title":"ESMO Open"},{"key":"B28","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12967-021-02773-x","article-title":"Multi-omics characterization and validation of invasiveness-related molecular features across multiple cancer types","volume":"19","author":"Bi","year":"2021","journal-title":"J Transl Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2023.1258902","article-title":"Machine learning combining multi-omics data and network algorithms identifies adrenocortical carcinoma prognostic biomarkers","volume":"10","author":"Martin-Hernandez","year":"2023","journal-title":"Front Mol Biosci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnac012","article-title":"Update on biology and genomics of adrenocortical carcinomas: Rationale for emerging therapies","volume":"43","author":"Lerario","year":"2022","journal-title":"Endocr Rev"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/cells12050755","article-title":"The characteristics of tumor microenvironment predict survival and response to immunotherapy in adrenocortical carcinomas","volume":"12","author":"Lai","year":"2023","journal-title":"Cells"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2953","article-title":"Integrated genomic characterization of adrenocortical carcinoma","volume":"46","author":"Assi\u00e9","year":"2014","journal-title":"Nat Genet"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.add0422","article-title":"Sexually dimorphic activation of innate antitumor immunity prevents adrenocortical carcinoma development","volume":"8","author":"Wilmouth","year":"2022","journal-title":"Sci Advances"},{"key":"B34","doi-asserted-by":"publisher","first-page":"253","DOI":"10.21037\/atm.2018.05.52","article-title":"The role of epithelial growth factors and insulin growth factors in the adrenal neoplasms","volume":"6","author":"Angelousi","year":"2018","journal-title":"Ann Trans Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae029","article-title":"Adrenocortical carcinomas: Molecular pathogenesis, treatment options, and emerging immunotherapy and targeted therapy approaches","volume":"29","author":"Chukkalore","year":"2024","journal-title":"Oncologist"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2298","article-title":"The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer","volume":"99","author":"O'Sullivan","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000036908","article-title":"Research progress and perspectives of noncoding RNAs in adrenocortical carcinoma: A review","volume":"103","author":"Xu","year":"2024","journal-title":"Med (Baltimore)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14721","article-title":"Pharmacological profile and effects of mitotane in adrenocortical carcinoma","volume":"87","author":"Corso","year":"2021","journal-title":"Brit J Clin Pharma"},{"key":"B39","article-title":"Results of the ADIUVO trial, the first randomized study on post-operative adjuvant mitotane in patients with adrenocortical carcinoma","volume-title":"Endocrine abstracts","author":"Corso","year":"2021"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(23)00231-0","article-title":"Good news for patients with adrenocortical carcinoma from the ADIUVO trial","volume":"11","author":"Reincke","year":"2023","journal-title":"Lancet Diabetes Endocrinology"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(23)00193-6","article-title":"Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study","volume":"11","author":"Terzolo","year":"2023","journal-title":"Lancet Diabetes Endocrinology"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1055\/a-0715-1946","article-title":"Advanced adrenocortical carcinoma \u2013 what to do when first-line therapy fails","volume":"127","author":"Megerle","year":"2019","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-1456","article-title":"Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma","volume":"94","author":"Barlaskar","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-3970","article-title":"Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors","volume":"70","author":"Doghman","year":"2010","journal-title":"Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-014-0182-1","article-title":"The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent\/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial","volume":"5","author":"Lerario","year":"2014","journal-title":"Horm Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.46","article-title":"Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma","volume":"108","author":"Naing","year":"2013","journal-title":"Br J Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz318","article-title":"Objective response and prolonged disease control of advanced adrenocortical carcinoma with cabozantinib","volume":"105","author":"Kroiss","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00095-0","article-title":"Cabozantinib monotherapy for advanced adrenocortical carcinoma: a single-arm, phase 2 trial","volume":"25","author":"Campbell","year":"2024","journal-title":"Lancet Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-1419","article-title":"Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial","volume":"97","author":"Kroiss","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.667798","article-title":"Effects of sorafenib, a tyrosin kinase inhibitor, on adrenocortical cancer","volume":"12","author":"Cerquetti","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-11-0918","article-title":"Phase II study of weekly paclitaxel and sorafenib as second\/third-line therapy in patients with adrenocortical carcinoma","volume":"166","author":"Berruti","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8827","article-title":"Co-inhibition of EGFR and IGF1R synergistically impacts therapeutically on adrenocortical carcinoma","volume":"7","author":"Xu","year":"2016","journal-title":"Oncotarget"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-0978","article-title":"Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R","volume":"90","author":"Ferruzzi","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2017.00031","article-title":"PPAR-\u03b3 agonists as antineoplastic agents in cancers with dysregulated IGF axis","volume":"8","author":"Vella","year":"2017","journal-title":"Front Endocrinol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1677\/ERC-09-0170","article-title":"Rosiglitazone impairs proliferation of human adrenocortical cancer: preclinical study in a xenograft mouse model","volume":"17","author":"Luconi","year":"2010","journal-title":"Endocrine-Related Cancer"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11111097","article-title":"Stimulated expression of CXCL12 in adrenocortical carcinoma by the PPARgamma ligand rosiglitazone impairs cancer progression","volume":"11","author":"Cantini","year":"2021","journal-title":"J Personalized Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1431","article-title":"Nutlin-3a as a novel anticancer agent for adrenocortical carcinoma with CTNNB1 mutation","volume":"7","author":"Hui","year":"2018","journal-title":"Cancer Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1186\/s40169-015-0080-3","article-title":"Targeting polo-like kinase 1, a regulator of p53, in the treatment of adrenocortical carcinoma","volume":"5","author":"Bussey","year":"2016","journal-title":"Clin Transl Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3892\/or.2023.8604","article-title":"Polo-like kinase 1 selective inhibitor BI2536 (dihydropteridinone) disrupts centrosome homeostasis via ATM-ERK cascade in adrenocortical carcinoma","volume":"50","author":"Lin","year":"2023","journal-title":"Oncol Rep"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.18632\/aging.101356","article-title":"A hypothesis-driven approach identifies CDK4 and CDK6 inhibitors as candidate drugs for treatments of adrenocortical carcinomas","volume":"9","author":"Hadjadj","year":"2017","journal-title":"Aging (Albany NY)"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.2009.292","article-title":"Antineoplastic effects of decitabine, an inhibitor of DNA promoter methylation, in adrenocortical carcinoma cells","volume":"145","author":"Suh","year":"2010","journal-title":"Arch Surg"},{"key":"B62","doi-asserted-by":"publisher","first-page":"9951","DOI":"10.1038\/s41598-022-14197-8","article-title":"Cytotoxic effects of targeted agent alone or with chemotherapy in the treatment of adenoid cystic carcinoma: a preclinical study","volume":"12","author":"Savarese","year":"2022","journal-title":"Sci Rep"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16464","article-title":"A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma","volume":"8","author":"Goncalves","year":"2017","journal-title":"Oncotarget"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e18680","article-title":"A pilot study of volumetric and density tumor analysis of ACC patients treated with vorinostat in a phase II clinical trial","volume":"9","author":"Malarkey","year":"2023","journal-title":"Heliyon"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1210\/en.2015-2052","article-title":"ATR-101, a selective and potent inhibitor of acyl-CoA acyltransferase 1, induces apoptosis in H295R adrenocortical cells and in the adrenal cortex of dogs","volume":"157","author":"LaPensee","year":"2016","journal-title":"Endocrinology"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/ERC-15-0527","article-title":"ATR-101 disrupts mitochondrial functions in adrenocortical carcinoma cells and","volume":"23","author":"Cheng","year":"2016","journal-title":"vivo. Endocr Relat Cancer"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-2163","article-title":"Inhibition of adrenocortical carcinoma cell proliferation by steroidogenic factor-1 inverse agonists","volume":"94","author":"Doghman","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B68","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1200\/JCO.19.01586","article-title":"PD-1 blockade in advanced adrenocortical carcinoma","volume":"38","author":"Raj","year":"2020","journal-title":"J Clin Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009074","article-title":"Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: adrenocortical carcinoma cohort","volume":"12","author":"Chae","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.4511","article-title":"Camrelizumab plus apatinib for previously treated advanced adrenocortical carcinoma: A single-arm, open-label, phase 2 trial","volume":"42","author":"Wei","year":"2024","journal-title":"JCO"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.449","article-title":"Phase I trial of systemic intravenous infusion of interleukin-13-Pseudomonas exotoxin in patients with metastatic adrenocortical carcinoma","volume":"4","author":"Liu-Chittenden","year":"2015","journal-title":"Cancer Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.878365","article-title":"Recent advances in IL-13R\u03b12-Directed cancer immunotherapy","volume":"13","author":"Knudson","year":"2022","journal-title":"Front Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1021\/acs.bioconjchem.6b00156","article-title":"Copper-based nanomaterials for cancer imaging and therapy","volume":"27","author":"Zhou","year":"2016","journal-title":"Bioconjugate Chem"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.15212\/bioi-2022-0010","article-title":"Targeted imaging of tumor associated macrophages in breast cancer","volume":"4","author":"Xu","year":"2023","journal-title":"Bio Integration"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15212\/bioi-2024-0012","article-title":"Non-invasive physical stimulation to modulate the tumor microenvironment: Unveiling a new frontier in cancer therapy","volume":"5","author":"Guo","year":"2024","journal-title":"Bio Integration"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114697","article-title":"Voluntary exercise sensitizes cancer immunotherapy via the collagen inhibition-orchestrated inflammatory tumor immune microenvironment","volume":"43","author":"Luo","year":"2024","journal-title":"Cell Rep"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.53388\/TMR20211227255","article-title":"The artificial intelligence watcher predicts cancer risk by facial features","volume":"7","author":"Zhang","year":"2022","journal-title":"Traditional Med Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1545012\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T08:10:13Z","timestamp":1741767013000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1545012\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":77,"alternative-id":["10.3389\/fimmu.2025.1545012"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1545012","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,12]]},"article-number":"1545012"}}